[go: up one dir, main page]

NO20004218D0 - Increasing the circulating half-life of an antibody-based fusion protein - Google Patents

Increasing the circulating half-life of an antibody-based fusion protein

Info

Publication number
NO20004218D0
NO20004218D0 NO20004218A NO20004218A NO20004218D0 NO 20004218 D0 NO20004218 D0 NO 20004218D0 NO 20004218 A NO20004218 A NO 20004218A NO 20004218 A NO20004218 A NO 20004218A NO 20004218 D0 NO20004218 D0 NO 20004218D0
Authority
NO
Norway
Prior art keywords
antibody
life
increasing
fusion protein
circulating half
Prior art date
Application number
NO20004218A
Other languages
Norwegian (no)
Other versions
NO20004218L (en
Inventor
Stephen D Gillies
Kin-Ming Lo
Yan Lan
John Wesolowski
Original Assignee
Lexigen Pharm Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lexigen Pharm Corp filed Critical Lexigen Pharm Corp
Publication of NO20004218D0 publication Critical patent/NO20004218D0/en
Publication of NO20004218L publication Critical patent/NO20004218L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70514—CD4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
NO20004218A 1998-02-25 2000-08-23 Increasing the circulating half-life of an antibody-based fusion protein NO20004218L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7588798P 1998-02-25 1998-02-25
PCT/US1999/003966 WO1999043713A1 (en) 1998-02-25 1999-02-24 Enhancing the circulating half-life of antibody-based fusion proteins

Publications (2)

Publication Number Publication Date
NO20004218D0 true NO20004218D0 (en) 2000-08-23
NO20004218L NO20004218L (en) 2000-10-24

Family

ID=22128576

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20004218A NO20004218L (en) 1998-02-25 2000-08-23 Increasing the circulating half-life of an antibody-based fusion protein

Country Status (12)

Country Link
EP (1) EP1060194A1 (en)
JP (1) JP2002505086A (en)
CN (1) CN1204147C (en)
AU (1) AU758240B2 (en)
BR (1) BR9908226A (en)
CA (1) CA2320403A1 (en)
CZ (1) CZ20003099A3 (en)
HK (1) HK1036286A1 (en)
HU (1) HUP0100813A3 (en)
NO (1) NO20004218L (en)
PL (1) PL199659B1 (en)
WO (1) WO1999043713A1 (en)

Families Citing this family (143)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030109680A1 (en) 2001-11-21 2003-06-12 Sunol Molecular Corporation Antibodies for inhibiting blood coagulation and methods of use thereof
US5986065A (en) 1997-03-10 1999-11-16 Sunol Molecular Corporation Antibodies for inhibiting blood coagulation and methods of use thereof
US7749498B2 (en) 1997-03-10 2010-07-06 Genentech, Inc. Antibodies for inhibiting blood coagulation and methods of use thereof
US20060235209A9 (en) 1997-03-10 2006-10-19 Jin-An Jiao Use of anti-tissue factor antibodies for treating thromboses
ES2221717T3 (en) 1997-12-08 2005-01-01 Emd Lexigen Research Center Corp. USEFUL HETERODIMERAS FUSION PROTEINS FOR DIRECTED IMMUNOTHERAPY AND GENERAL IMMUNOSTIMULATION.
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
US6242195B1 (en) 1998-04-02 2001-06-05 Genentech, Inc. Methods for determining binding of an analyte to a receptor
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
KR100887482B1 (en) 1999-01-15 2009-03-10 제넨테크, 인크. Polypeptide Variants with Altered Effector Function
US7067110B1 (en) 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
US6617135B1 (en) 1999-08-09 2003-09-09 Emd Lexigen Research Center Corp. Multiple cytokine protein complexes
GB9926084D0 (en) * 1999-11-03 2000-01-12 King S College London Recombinant fusion molecules
JP2003514552A (en) 1999-11-12 2003-04-22 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング Erythropoietin morphology with improved properties
PT1252192E (en) * 2000-02-11 2007-01-31 Merck Patent Gmbh Enhancing the circulating half-life of antibody-based fusion proteins
WO2001079299A1 (en) 2000-04-13 2001-10-25 The Rockefeller University Enhancement of antibody-mediated immune responses
PL358582A1 (en) 2000-06-29 2004-08-09 Merck Patent Gmbh Enhancement of antibody-cytokine fusion protein mediated immune responses by combined treatment with immunocytokine uptake enhancing agents
DE10045591A1 (en) * 2000-09-15 2002-04-04 Klaus Pfizenmaier Site-specific, antibody-mediated activation of proapoptotic cytokines - AMAIZe (Antibody-Mediated Apoptosis Inducing Cytokines)
US7658921B2 (en) 2000-12-12 2010-02-09 Medimmune, Llc Molecules with extended half-lives, compositions and uses thereof
US7083784B2 (en) 2000-12-12 2006-08-01 Medimmune, Inc. Molecules with extended half-lives, compositions and uses thereof
AU2011253690C1 (en) * 2000-12-12 2018-01-18 Board Of Regents, The University Of Texas System Molecules with extended half-lives, compositions and uses thereof
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
HUP0303428A2 (en) * 2001-03-07 2004-01-28 Merck Patent Gmbh. Expression technology for proteins containing a hybrid isotype antibody moiety
US6992174B2 (en) 2001-03-30 2006-01-31 Emd Lexigen Research Center Corp. Reducing the immunogenicity of fusion proteins
ATE502053T1 (en) 2001-05-03 2011-04-15 Merck Patent Gmbh RECOMBINANT TUMOR-SPECIFIC ANTIBODIES AND USE THEREOF
TWI338009B (en) * 2001-10-29 2011-03-01 Genentech Inc Antibodies for inhibiting blood coagulation and methods of use thereof
DK1454138T3 (en) 2001-12-04 2012-02-13 Merck Patent Gmbh Immunocytokines with modulated selectivity
AU2003222664A1 (en) * 2002-04-18 2003-11-03 Genencor International, Inc. Production of functional antibodies in filamentous fungi
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
US8946387B2 (en) 2002-08-14 2015-02-03 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
US8968730B2 (en) 2002-08-14 2015-03-03 Macrogenics Inc. FcγRIIB specific antibodies and methods of use thereof
WO2004035752A2 (en) * 2002-10-15 2004-04-29 Protein Design Labs, Inc. ALTERATION OF FcRn BINDING AFFINITIES OR SERUM HALF-LIVES OF ANTIBODIES BY MUTAGENESIS
US7217797B2 (en) * 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
DE60333121D1 (en) 2002-12-17 2010-08-05 Merck Patent Gmbh PERS 14.18 BINDING GD2 AND ITS FUSION WITH IL-2
US7960512B2 (en) 2003-01-09 2011-06-14 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
WO2004063351A2 (en) 2003-01-09 2004-07-29 Macrogenics, Inc. IDENTIFICATION AND ENGINEERING OF ANTIBODIES WITH VARIANT Fc REGIONS AND METHODS OF USING SAME
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
SI2077121T1 (en) 2003-05-06 2011-07-29 Syntonix Pharmaceuticals Inc Clotting factor VII-Fc chimeric proteins for treatment of a hemostatic disorder
JP2005073528A (en) * 2003-08-28 2005-03-24 Genetics Inst Llc Method for inhibiting adhesion of blood to biological tissue in biological system, and composition for being used for the method
JP2007531707A (en) 2003-10-15 2007-11-08 ピーディーエル バイオファーマ， インコーポレイテッド Modification of Fc fusion protein serum half-life by mutagenesis of heavy chain constant region positions 250, 314 and / or 428 of IG
KR101163424B1 (en) 2003-12-30 2012-07-13 메르크 파텐트 게엠베하 Il-7 fusion proteins
CN1902222A (en) 2003-12-31 2007-01-24 默克专利有限公司 Fc-erythropoietin fusion protein with improved pharmacokinetics
JP2007517506A (en) 2004-01-05 2007-07-05 イーエムディー・レキシゲン・リサーチ・センター・コーポレーション Targeting compounds
US7632497B2 (en) 2004-11-10 2009-12-15 Macrogenics, Inc. Engineering Fc Antibody regions to confer effector function
RU2437893C2 (en) 2004-12-09 2011-12-27 Мерк Патент Гмбх Il-7 versions with low immunising capacity
CA2605024C (en) 2005-04-15 2018-05-22 Macrogenics, Inc. Covalent diabodies and uses thereof
US9284375B2 (en) 2005-04-15 2016-03-15 Macrogenics, Inc. Covalent diabodies and uses thereof
US9963510B2 (en) 2005-04-15 2018-05-08 Macrogenics, Inc. Covalent diabodies and uses thereof
US11254748B2 (en) 2005-04-15 2022-02-22 Macrogenics, Inc. Covalent diabodies and uses thereof
RU2423381C2 (en) 2005-07-25 2011-07-10 Трабьон Фармасьютикалз, Инк. Decreasing b-cell count with using cd37-specific and cd20-specific binding molecules
WO2007021841A2 (en) 2005-08-10 2007-02-22 Macrogenics, Inc. Identification and engineering of antibodies with variant fc regions and methods of using same
CA2654317A1 (en) 2006-06-12 2007-12-21 Trubion Pharmaceuticals, Inc. Single-chain multivalent binding proteins with effector function
EP2032159B1 (en) 2006-06-26 2015-01-07 MacroGenics, Inc. Combination of fcgammariib antibodies and cd20-specific antibodies and methods of use thereof
SI2029173T1 (en) 2006-06-26 2016-12-30 Macrogenics, Inc. Fc riib-specific antibodies and methods of use thereof
PL1873166T3 (en) * 2006-06-30 2011-03-31 Conaris Res Institute Ag Improved sgp 130Fc dimers
WO2008140603A2 (en) 2006-12-08 2008-11-20 Macrogenics, Inc. METHODS FOR THE TREATMENT OF DISEASE USING IMMUNOGLOBULINS HAVING FC REGIONS WITH ALTERED AFFINITIES FOR FCγR ACTIVATING AND FCγR INHIBITING
TW200907056A (en) * 2007-03-28 2009-02-16 Astrazeneca Ab New method
PE20140196A1 (en) 2007-08-09 2014-03-19 Boehringer Ingelheim Int ANTI-CD37 ANTIBODIES
DK2219672T3 (en) 2007-11-09 2016-05-17 Peregrine Pharmaceuticals Inc The anti-VEGF antibody compositions and methods
WO2009117030A2 (en) 2007-12-19 2009-09-24 Macrogenics, Inc. Improved compositions for the prevention and treatment of smallpox
US20110033378A1 (en) 2008-01-18 2011-02-10 Medlmmune, Llc. Cysteine Engineered Antibodies For Site-Specific Conjugation
EP3045475B1 (en) 2008-04-02 2017-10-04 MacroGenics, Inc. Bcr-complex-specific antibodies and methods of using same
CA2720368C (en) 2008-04-02 2017-08-22 Macrogenics, Inc. Her2/neu-specific antibodies and methods of using same
EP2132228B1 (en) 2008-04-11 2011-06-22 Emergent Product Development Seattle, LLC Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
TWI440469B (en) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
EP2373689A1 (en) 2008-12-12 2011-10-12 MedImmune, LLC Crystals and structure of a human igg fc variant with enhanced fcrn binding
AU2010225951B2 (en) * 2009-03-19 2014-03-13 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical formulation containing improved antibody molecules
EP2233500A1 (en) 2009-03-20 2010-09-29 LFB Biotechnologies Optimized Fc variants
CA2759333A1 (en) 2009-04-22 2010-10-28 Merck Patent Gmbh Antibody fusion proteins with modified fcrn binding sites
US20120134984A1 (en) 2009-06-01 2012-05-31 Olga Lubman Molecules with extended half-lives and uses thereof
BRPI1015234A2 (en) 2009-06-22 2018-02-20 Medimmune Llc fc regions designed for site specific conjugation.
PT2486141T (en) 2009-10-07 2018-05-09 Macrogenics Inc Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and methods for their use
BR112012013330A2 (en) 2009-12-02 2017-03-28 Acceleron Pharma Inc compositions and methods for increasing fc fusion protein serum half life
TWI505838B (en) 2010-01-20 2015-11-01 Chugai Pharmaceutical Co Ltd Stabilized antibody
PE20170779A1 (en) 2010-03-04 2017-07-04 Macrogenics Inc ANTIBODIES REACTIVE WITH B7-H3, IMMUNOLOGICALLY ACTIVE FRAGMENTS OF THE SAME AND USES OF THE SAME
PH12012501751A1 (en) 2010-03-04 2012-11-12 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
SG187682A1 (en) 2010-08-02 2013-03-28 Macrogenics Inc Covalent diabodies and uses thereof
UA112062C2 (en) 2010-10-04 2016-07-25 Бьорінгер Інгельхайм Інтернаціональ Гмбх CD33-Binding Agent
WO2012069433A2 (en) 2010-11-23 2012-05-31 Glaxo Group Limited Antigen binding proteins
US20130236467A1 (en) 2010-11-24 2013-09-12 Jeremy Griggs Multispecific antigen binding proteins targeting hgf
EA201390923A1 (en) 2010-12-22 2013-12-30 Сефалон Острэйлиа Пти Лтд. MODIFIED ANTIBODY WITH AN IMPROVED ELEMENTATION SEMIUM PERIOD
SI2691417T1 (en) 2011-03-29 2018-11-30 Roche Glycart Ag Antibody fc variants
EA201892619A1 (en) 2011-04-29 2019-04-30 Роше Гликарт Аг IMMUNOCONJUGATES CONTAINING INTERLEUKIN-2 MUTANT POLYPETIPS
EA201391753A1 (en) 2011-05-21 2014-08-29 Макродженикс, Инк. DOMAINS CONNECTING WITH DEIMMUNIZED SERUM AND THEIR APPLICATION TO INCREASE THE TIME OF HALF-DURATION
EP2718328A4 (en) 2011-06-08 2014-12-24 Acceleron Pharma Inc Compositions and methods for increasing serum half-life
CA2842099A1 (en) 2011-07-27 2013-01-31 Glaxo Group Limited Antigen binding constructs
ES2819075T3 (en) 2011-10-11 2021-04-14 Viela Bio Inc Support matrices derived from TN3 specific for CD40L and their methods of use
US11147852B2 (en) 2011-12-23 2021-10-19 Pfizer Inc. Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
EP2872534B1 (en) 2012-07-13 2018-08-08 Roche Glycart AG Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases
BR112015002091A2 (en) 2012-08-02 2017-12-12 Hoffmann La Roche method for producing a polypeptide, polypeptide, use of a polypeptide and composition
US20140044675A1 (en) 2012-08-10 2014-02-13 Roche Glycart Ag Interleukin-2 fusion proteins and uses thereof
EP2888279A1 (en) 2012-08-22 2015-07-01 Glaxo Group Limited Anti lrp6 antibodies
TWI682941B (en) 2013-02-01 2020-01-21 美商再生元醫藥公司 Antibodies comprising chimeric constant domains
US9487587B2 (en) 2013-03-05 2016-11-08 Macrogenics, Inc. Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
DK2968520T3 (en) 2013-03-14 2021-08-09 Macrogenics Inc BISPECIFIC MOLECULES THAT ARE IMMUNORE ACTIVE WITH IMMUNE EFFECTOR CELLS EXPRESSING AN ACTIVATING RECEPTOR
HUE049957T2 (en) 2013-03-15 2020-11-30 Glaxosmithkline Ip Dev Ltd Anti-lag-3 binding proteins
US11384149B2 (en) 2013-08-09 2022-07-12 Macrogenics, Inc. Bi-specific monovalent Fc diabodies that are capable of binding CD32B and CD79b and uses thereof
UA116479C2 (en) 2013-08-09 2018-03-26 Макродженікс, Інк. SPECIFIC MONOVALENT Fc-DIATELY CONNECTING BACKGROUND OF THE CD32B AND CD79b AND ITS APPLICATION
EP2840091A1 (en) 2013-08-23 2015-02-25 MacroGenics, Inc. Bi-specific diabodies that are capable of binding gpA33 and CD3 and uses thereof
EP2839842A1 (en) 2013-08-23 2015-02-25 MacroGenics, Inc. Bi-specific monovalent diabodies that are capable of binding CD123 and CD3 and uses thereof
EA201992609A1 (en) 2014-02-06 2020-03-04 Ф.Хоффманн-Ля Рош Аг FILLED PROTEINS CONTAINING INTERLEUKIN-2 AND THEIR APPLICATIONS
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
TWI701042B (en) 2014-03-19 2020-08-11 美商再生元醫藥公司 Methods and antibody compositions for tumor treatment
JP6832709B2 (en) 2014-05-16 2021-02-24 メディミューン，エルエルシー Molecules with modified neonatal Fc receptor binding for enhanced therapeutic and diagnostic properties
WO2015196070A1 (en) 2014-06-20 2015-12-23 Genentech, Inc. Chagasin-based scaffold compositions, methods, and uses
CN107106654B (en) 2014-08-11 2021-06-11 德里尼亚公司 Modified IL-2 variants that selectively activate regulatory T cells for treatment of autoimmune diseases
AU2015323860B2 (en) 2014-09-29 2021-05-27 Duke University Bispecific molecules comprising an HIV-1 envelope targeting arm
MX385543B (en) 2014-11-17 2025-03-18 Regeneron Pharma USE OF A BISPECIFIC ANTIBODY TO TREAT B-CELL CANCER.
EP3263132B1 (en) 2015-02-27 2023-12-06 Chugai Seiyaku Kabushiki Kaisha Composition for treating il-6-related diseases
ES2846748T3 (en) 2015-03-30 2021-07-29 Regeneron Pharma Heavy chain constant regions with reduced binding to Fc gamma receptors
GB201506389D0 (en) * 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
GB201506393D0 (en) * 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
EP3328427B1 (en) 2015-07-27 2024-05-29 The General Hospital Corporation Antibody derivatives with conditionally enabled effector function
MX2018002610A (en) 2015-09-02 2018-09-27 Immutep Sas Anti-LAG-3 Antibodies.
TWI799366B (en) 2015-09-15 2023-04-21 美商建南德克公司 Cystine knot scaffold platform
US11352426B2 (en) 2015-09-21 2022-06-07 Aptevo Research And Development Llc CD3 binding polypeptides
KR20210016479A (en) 2015-12-04 2021-02-15 노파르티스 아게 Antibody cytokine engrafted compositions and methods of use for immunoregulation
US20170204154A1 (en) 2016-01-20 2017-07-20 Delinia, Inc. Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
MX394519B (en) 2016-04-15 2025-03-24 Macrogenics Inc Novel b7-h3 binding molecules, antibody drug conjugates thereof and methods of use thereof
CA3026477A1 (en) 2016-06-20 2017-12-28 Kymab Limited Anti-pd-l1 antibodies
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
JP2019534858A (en) 2016-09-09 2019-12-05 ジェネンテック， インコーポレイテッド Selective peptide inhibitor of FRIZZLED
CN109952370B (en) * 2016-10-19 2023-09-08 豪夫迈·罗氏有限公司 Methods for producing immunoconjugates
EP3534947A1 (en) 2016-11-03 2019-09-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
WO2018089420A1 (en) 2016-11-08 2018-05-17 Delinia, Inc. Il-2 variants for the treatment of autoimmune diseases
EP3620531A4 (en) 2017-05-02 2021-03-17 National Center of Neurology and Psychiatry Method for predicting and evaluating therapeutic effect in diseases related to il-6 and neutrophils
PE20200303A1 (en) 2017-05-24 2020-02-06 Novartis Ag ANTIBODY PROTEINS GRAFTED WITH CYTOKINE AND METHODS OF USE IN THE TREATMENT OF CANCER
JOP20190271A1 (en) 2017-05-24 2019-11-21 Novartis Ag Antibody-cytokine engrafted proteins and methods of use for immune related disorders
EP3694885A1 (en) 2017-10-14 2020-08-19 CytomX Therapeutics, Inc. Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof
EP3728302A1 (en) 2017-12-19 2020-10-28 Xencor, Inc. Engineered il-2 fc fusion proteins
AU2019331024A1 (en) 2018-08-31 2021-03-18 Regeneron Pharmaceuticals, Inc. Dosing strategy that mitigates cytokine release syndrome for CD3/C20 bispecific antibodies
WO2020168554A1 (en) * 2019-02-22 2020-08-27 武汉友芝友生物制药有限公司 Modified fc fragment, antibody comprising same, and application thereof
KR20220041915A (en) 2019-08-06 2022-04-01 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 Biopharmaceutical compositions and related methods
JP2024521187A (en) 2021-05-28 2024-05-28 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド Combination Therapy for the Treatment of Cancer
EP4380981A2 (en) 2021-08-03 2024-06-12 GlaxoSmithKline Intellectual Property Development Limited Biopharmaceutical compositions and stable isotope labeling peptide mapping method
CA3233953A1 (en) 2021-10-05 2023-04-13 Matthew Bruce Combination therapies for treating cancer
CA3241017A1 (en) 2021-12-17 2023-06-22 Robert Ferris Combination therapies for hiv infections and uses thereof
AR129182A1 (en) 2022-04-29 2024-07-24 23Andme Inc Antigen-binding proteins
AU2023329062A1 (en) 2022-08-25 2025-03-06 Glaxosmithkline Intellectual Property Development Limited Antigen binding proteins and uses thereof
TW202430564A (en) 2022-10-20 2024-08-01 英商葛蘭素史密斯克藍智慧財產權有限公司 Antigen binding proteins
TW202432582A (en) 2022-11-02 2024-08-16 英商Ｖｉｉｖ醫療保健英國(Ｎｏ 5)有限公司 Antigen binding proteins

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9511935D0 (en) * 1995-06-13 1995-08-09 Smithkline Beecham Plc Novel compound
AU2527397A (en) * 1996-03-13 1997-10-01 Protein Design Labs, Inc. Fas ligand fusion proteins and their uses

Also Published As

Publication number Publication date
HUP0100813A2 (en) 2001-06-28
EP1060194A1 (en) 2000-12-20
AU758240B2 (en) 2003-03-20
AU2784299A (en) 1999-09-15
CA2320403A1 (en) 1999-09-02
BR9908226A (en) 2000-10-24
PL199659B1 (en) 2008-10-31
WO1999043713A1 (en) 1999-09-02
NO20004218L (en) 2000-10-24
HUP0100813A3 (en) 2003-08-28
CN1204147C (en) 2005-06-01
JP2002505086A (en) 2002-02-19
HK1036286A1 (en) 2001-12-28
PL342497A1 (en) 2001-06-04
CN1291995A (en) 2001-04-18
CZ20003099A3 (en) 2002-04-17

Similar Documents

Publication Publication Date Title
NO20004218D0 (en) Increasing the circulating half-life of an antibody-based fusion protein
FI971479L (en) Fused pyrrolocarbazoles
TR199501568A2 (en) Pioneers of Tasiki.
CY2008013I2 (en) ARYL FUSED AZAPOLYCYCLIC COMPOUNDS
FR2770110B1 (en) CASE, OF THE MAKEUP CASE TYPE
CY2005008I2 (en) ANTI-VEGF ANTIBODIES
DE69530137D1 (en) Tapered fusion cage
ID22849A (en) SULMAFIDA-METALOPROTEASE OBSTACLES
DE59703000D1 (en) Self seller
FR2717769B1 (en) CV joint.
FI973804A0 (en) Orala sammansaettningar av levosimendan
BR9704567A (en) Elements of fusion systems
DK0917879T3 (en) Improved protein stabilization method
ID27203A (en) SEAL
NO980566D0 (en) Allergen-XCD32 fusion proteins
DE69627455D1 (en) joint assembly
BR9901328B1 (en) fuser member.
FI972553A0 (en) Reactor housing joint
NO993584D0 (en) Bias type connection
MX224819B (en) COSMETIC EMPLOYMENT OF DERIVATIVES OF BIS (RESORCINIL) TRIACINA.
FI974244A0 (en) Foerfarande Foer kompressering av en bild
ID25903A (en) OFTALMIK LENS HOLOGRAFIK
DK0862197T3 (en) Fused Connection
NO982014D0 (en) Procedure for calculating the duration of connections
ES1030440Y (en) JOINT PROSTHESIS.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application